Author

Yan Luo 1

1 Abbvie Inc., North Chicago, United States

ADHERENCE TO PRESCRIBED DOSES OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN THE PHASE 3 PEARL-II, PEARL-III, AND PEARL-IV TRIALS

David E. Bernstein, Rui Tato Marinho, Daniel E. Cohen, Fritz Bredeek, Ferenc Schneider, Gunnar Norkrans, Manuela Curescu, Michael Bennett, Marina Maevskaya, Jeffrey Fessel, Yan Luo, Jeffrey Enejosa

LOW INCIDENCE OF HYPERBILIRUBINAEMIA EVENTS WITH ABT-450/R/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE-1 INFECTED PATIENTS

Manuel Romero-Gomez, Rui Tato Marinho, Ramon Vila, David E. Bernstein, Federico Rodriguez-Perez, Tarek Hassanein, K. Reddy, Naoky Tsai, Sandra Lovell, Jeffrey Enejosa, Yan Luo, Daniel E. Cohen, Marcos Pedrosa, Massimo Colombo

MANAGEMENT OF HAEMOGLOBIN DECREASE IN PATIENTS TREATED WITH ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS

Daniel Forton, Hendrik Reesink, David E. Bernstein, Thomas Sepe, John Vierling, William King, Yiran Hu, Jeffrey Enejosa, Daniel E. Cohen, Yan Luo, Marcos Pedrosa, Peter Ferenci

SAFETY OF ABT-450/R/OMBITASVIR + DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS: RESULTS FROM PEARL II, PEARL III, AND PEARL IV

Richard Aspinall, Jacob Lalezari, Yan Luo, Ronald Pruitt, Velimir Luketic, Giovanni Gaeta, Iwona Olszok, William King, Selim Gürel, Yiran Hu, Jeffrey Enejosa, Daniel E. Cohen, Nancy Shulman

SUSTAINED VIROLOGIC RESPONSE RATE OF 96% IN HCV GENOTYPE 1A-INFECTED PATIENTS TREATED WITH OMBITASVIR/PARITAPREVIR/R AND DASABUVIR WITH RIBAVIRIN

Heiner Wedemeyer, Paul Pockros, Samuel S. Lee, Edward Gane, Christophe Moreno, Simone Strasser, Victor De Ledinghen, Andreas Maieron, Wangang Xie, Roger Trinh, Yan Luo, Fernando Tatsch, Vinod Rustgi

Item 1 - 5 / 5
1